Why Is Silicon Valley Shunning Juul?

As VC funds shovel money into start-ups, they have noticeably stayed away from Juul, even as it exploded in growth and catapulted to become the most valuable vape brand. Erin Griffith, correspondent for the New York Times, said investors appear to be taking a moral stand, even as they simultaneously invest in other nicotine-delivery products. For full interview [click here](https://cheddar.com/videos/silicon-valley-shuns-juul-supports-nicotine-elsewhere).

More In Business

Will Mr. Musk Go to Washington? Joining Trump Could Make Trouble for X

CEO of tastytrade Scott Sheridan weighs in on the possibility of Elon Musk joining Trump’s administration, plus the DOJ’s suit against Ticketmaster.

Teeing Up Change: The 14-Year-Old CEO Revolutionizing Girls' Golf Apparel

Featherie, a line of sustainable and functional golf wear for girls, fills a void in the market, catering to the increasing number of female junior golfers.

The Economic ‘Pain’ Fed Chief Jerome Powell Warned About Is Here

Data shows the economy grew less than expected in the first three months of the year, as consumers became more price conscious and spent less.

Will Live Nation and Ticketmaster Actually Be Broken Up?

The CEO of LiveOne, Rob Ellin, discusses the DOJ's lawsuit against Live Nation and Ticketmaster, how will if affect you and the future of live events. Watch!

The Future of Ether ETFs After That SEC Ruling

CoinShares CEO, Jean-Marie Mognetti, joins Cheddar to discuss what's next for ether ETFs and other cryptocurrency after the SEC surprise ruling.

The Trending, Fastest-Growing Summer Destinations Will Surprise You

From the Vegas strip to breathtaking national parks, we’re obsessed.

Nvidia's Blockbuster Run Is Just Getting Started

Nvidia did a record $26 billion in sales in the latest quarter. And get ready for the stock to keep climbing, because the A.I. boom is just getting started.

Perspective Therapeutics Is Creating New Ways to Fight Cancer

In honor of National Cancer Research Month, Perspective Therapeutics discusses its latest treatment — currently in clinical trials — that targets cancer cells d

When It Comes to the Economy, There’s ‘A Lot to Be Optimistic About’

Business is booming, interest rate cuts aren’t desperately needed, and, consumers are in what one analyst calls ‘pretty good shape.’

More People Are Making 'no-buy year' Pledges. Should You?

The self-imposed rules of a no-buy challenge are simple: participants pledge to stop buying non-essential items.

Load More